Difference between revisions of "Mitomycin (Mutamycin)"
Jump to navigation
Jump to search
m |
m |
||
Line 26: | Line 26: | ||
<references/> | <references/> | ||
+ | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Vesicant chemotherapy]] | [[Category:Vesicant chemotherapy]] |
Revision as of 16:28, 24 October 2014
General information
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Mitomycin (Mutamycin) patient drug information (Chemocare)[3]
- Mitomycin (Mutamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/24/1981: Initial FDA approval
Also known as
Mitomycin-C, MTC, Mitozytrex